Press Releases
Creative Bioarray Release Validated Preclinical Models to Support All Stages of Drug Discovery
Jul 29, 2020, 11:07 AM
by
The development of compounds from discovery to clinical is a huge and expensive decision, which must be based on correct information. Due to the huge in vivo model library, the extensive experience of in-house scientists, the in-depth research on pharmacology, as well as the proprietary technology platform, Creative Bioarray has a large number of widely validated preclinical models. There are more than 300 proven animal models of diseases, covering more than 40 different diseases in the fields of cancer, bone, autoimmunity and inflammation.
There is a major obstacle to the evaluation of new human immunotherapies due to a lack of experimental models with a fully functional human immune system. Therefore, the development of humanized experimental models still is an unmet need in immunotherapy research. Creative Bioarray is committed to furthering immuno-oncology research, at present, developing a humanized mouse model that utilizes the human immune system against human tumors.
The humanized mouse model can be used to provide:
• Microenvironment that mimics the response of human immune cells
• Interaction between the immune system and human tumor cells or tissues
• A cost-effective platform to assess the effectiveness of potential new drugs to modulate the immune system without putting patients at risk
With years of experience in developing humanized mouse models with functional human hematopoietic and lymphatic systems, Creative Bioarray has established a reliable humanized mouse model with a powerful functional human immune system, setting the goal to provide high-quality and consistent animals at any time to promote cutting-edge research on human immune response.
Creative Bioarray provides a set of widely validated syngeneic mouse models for pre-clinical immunotherapy research, which is used to inquire about new immuno-oncology treatment methods. The types of mouse models include subcutaneous, in situ and metastatic, and the syngeneic mouse model kit covering different cancer types. WIth one of the most extensive collections of isogenic tumor models in the industry, Creative Bioarray specializes in situ implantation. The models offered involve good characteristics and are benchmarked against the most common immune checkpoint inhibitors, other immunomodulators and combination therapies.
The patient-derived tumor xenograft mouse model (PDX model) is a commonly used oncology research platform for studying tumor biology and testing new anti-cancer therapies. The PDX model retains the pathological and genomic characteristics of each patient's tumor. PDX models were generated by using freshly excised patient tumors (which do not require immediate in vitro culture steps to better preserve genomic integrity and tumor heterogeneity) and immediately transplanted them into immunocompromised rodents.
Creative Bioarray has established many PDX models, covering various solid tumors, such as ovarian cancer, lung cancer and colorectal cancer, and hematopoietic tumors, such as leukemia. All these PDX models have been evaluated by histopathological examination and comprehensive gene expression analysis.
The genetically engineered mouse (GEM) model is a promising alternative to xenotransplantation models for biological and therapeutic research, which is generated by introducing gene mutations related to specific human malignancies. Such mutant genes may be functionally acquired oncogenes or loss-of-function tumor suppressor genes that are expressed constitutively or conditionally in mouse models. To date, GEM models have been developed for many common tumor types, including lung cancer, prostate cancer, breast cancer, colon cancer and pancreatic cancer. GEMM can play a key role in elucidating the mechanisms of treatment response and innate resistance to chemotherapy and targeted drugs.
Creative Bioarray is committed to providing the most innovative preclinical models to describe the underlying mechanisms of the disease and enable researchers to select the most promising candidates. The models offered by Creative Bioarray will also be applied to the potential areas of therapeutic interest that have not been clear so far, and providing new and interesting directions for the development of new therapeutic agents.
There is a major obstacle to the evaluation of new human immunotherapies due to a lack of experimental models with a fully functional human immune system. Therefore, the development of humanized experimental models still is an unmet need in immunotherapy research. Creative Bioarray is committed to furthering immuno-oncology research, at present, developing a humanized mouse model that utilizes the human immune system against human tumors.
The humanized mouse model can be used to provide:
• Microenvironment that mimics the response of human immune cells
• Interaction between the immune system and human tumor cells or tissues
• A cost-effective platform to assess the effectiveness of potential new drugs to modulate the immune system without putting patients at risk
With years of experience in developing humanized mouse models with functional human hematopoietic and lymphatic systems, Creative Bioarray has established a reliable humanized mouse model with a powerful functional human immune system, setting the goal to provide high-quality and consistent animals at any time to promote cutting-edge research on human immune response.
Creative Bioarray provides a set of widely validated syngeneic mouse models for pre-clinical immunotherapy research, which is used to inquire about new immuno-oncology treatment methods. The types of mouse models include subcutaneous, in situ and metastatic, and the syngeneic mouse model kit covering different cancer types. WIth one of the most extensive collections of isogenic tumor models in the industry, Creative Bioarray specializes in situ implantation. The models offered involve good characteristics and are benchmarked against the most common immune checkpoint inhibitors, other immunomodulators and combination therapies.
The patient-derived tumor xenograft mouse model (PDX model) is a commonly used oncology research platform for studying tumor biology and testing new anti-cancer therapies. The PDX model retains the pathological and genomic characteristics of each patient's tumor. PDX models were generated by using freshly excised patient tumors (which do not require immediate in vitro culture steps to better preserve genomic integrity and tumor heterogeneity) and immediately transplanted them into immunocompromised rodents.
Creative Bioarray has established many PDX models, covering various solid tumors, such as ovarian cancer, lung cancer and colorectal cancer, and hematopoietic tumors, such as leukemia. All these PDX models have been evaluated by histopathological examination and comprehensive gene expression analysis.
The genetically engineered mouse (GEM) model is a promising alternative to xenotransplantation models for biological and therapeutic research, which is generated by introducing gene mutations related to specific human malignancies. Such mutant genes may be functionally acquired oncogenes or loss-of-function tumor suppressor genes that are expressed constitutively or conditionally in mouse models. To date, GEM models have been developed for many common tumor types, including lung cancer, prostate cancer, breast cancer, colon cancer and pancreatic cancer. GEMM can play a key role in elucidating the mechanisms of treatment response and innate resistance to chemotherapy and targeted drugs.
Creative Bioarray is committed to providing the most innovative preclinical models to describe the underlying mechanisms of the disease and enable researchers to select the most promising candidates. The models offered by Creative Bioarray will also be applied to the potential areas of therapeutic interest that have not been clear so far, and providing new and interesting directions for the development of new therapeutic agents.
